GlassScriptPhysician profile
Tariq Javed
NPI 1871579235
$20,064.70
in general payments reported to CMS, 2019-2025
28 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,521 · 2020: $3,183 · 2021: $3,032 · 2022: $4,645 · 2023: $1,968 · 2024: $2,129 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $5,814.04 | 2019-2024 | Senza |
| 4web, INC. | $5,490.86 | 2020-2025 | Spine Truss System |
| Medtronic, INC. | $2,333.83 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Strata |
| Medtronic USA, INC. | $2,248.41 | 2019-2020 | |
| Abbott Laboratories | $852.55 | 2021-2024 | Proclaim, Eterna |
| Stryker Corporation | $539.61 | 2019-2023 | Bio4 |
| Globus Medical, INC. | $471.04 | 2025 | Senza, Vyrsa V1 |
| Biotronik Nro, INC. | $373.79 | 2023-2024 | Prospera, Biotronik |
| Intrinsic Therapeutics | $339.81 | 2024-2025 | Barricaid Acd (Annular Closure Device) |
| Saluda Medical Americas, INC. | $246.43 | 2025 | Evoke |
| Boston Scientific Corporation | $170.71 | 2024 | |
| Nanovis LLC | $150.23 | 2022 | |
| Vertos Medical, INC. | $148.33 | 2024 | Mild Device Kit |
| Orthofix Medical, INC. | $142.16 | 2022 | |
| Spineart USA INC | $141.91 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Providence Medical Technology, INC. | $131.89 | 2025 | |
| Nuvasive, INC. | $126.62 | 2022 | |
| Baxter Healthcare | $122.76 | 2023 | Floseal |
| Spine Wave, INC. | $39.24 | 2023 | Spinal Implant, Annex Adjacent Level System |
| Davol INC. | $36.13 | 2025 | Arista |
| Vertex Pharmaceuticals Incorporated | $32.45 | 2025 | |
| Microtransponder, INC. | $23.64 | 2025 | |
| Si-Bone, INC. | $22.20 | 2022 | |
| Bioventus LLC | $20.38 | 2023 | Bonescalpel |
| Astrazeneca Pharmaceuticals LP | $18.81 | 2024 | Andexxa |
| Otsuka America Pharmaceutical, INC. | $14.62 | 2025 | |
| Lemaitre Vascular, INC. | $12.25 | 2023 | Anastoclip Gc 8cm (Medium) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$105,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.